Remove 2011 Remove Protein Expression Remove Protein Production
article thumbnail

Key considerations before commencing cell line development

Drug Target Review

A good introduction to the use of CHO cells for biotherapeutics production can be found in an article commemorating the 20th anniversary of the approval of a product produced using CHO cells. 2011), 108: 2141-2150 Schmieder V, Fieder J, et al. 2016), 32: 1301-1307 Matasci M, Baldo L, et al.

article thumbnail

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

The Pharma Data

Results demonstrated a substantial decrease in the time to diagnosis from >6 years of age (2011-2015) to <2 years of age (2019-2020). protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological Na V 1.1 .–( BUSINESS WIRE )– Stoke Therapeutics , Inc.